Mostrar el registro sencillo del ítem
Calcifediol or Corticosteroids in the Treatment of COVID-19: An Observational Study
dc.contributor.author | Entrenas-Castillo, Marta | |
dc.contributor.author | Entrenas-Costa, Luis Manuel | |
dc.contributor.author | Pata, María P. | |
dc.contributor.author | Jurado-Gámez, Bernabé | |
dc.contributor.author | Muñoz-Corroto, Cristina | |
dc.contributor.author | Gomez-Rebollo, Cristina | |
dc.contributor.author | Mira-Padilla, Estefanía | |
dc.contributor.author | Bouillon, Roger | |
dc.contributor.author | Quesada Gómez, José Manuel | |
dc.date.accessioned | 2024-06-21T10:31:19Z | |
dc.date.available | 2024-06-21T10:31:19Z | |
dc.date.issued | 2024 | |
dc.identifier.uri | http://hdl.handle.net/10396/28542 | |
dc.description.abstract | Medical treatment of coronavirus 19 disease (COVID-19) is a therapeutic challenge. The available data strongly suggest that calcifediol treatment may reduce the severity of COVID-19, and corticosteroids are the treatment of choice worldwide for severe COVID-19. Both have a very similar action profile, and their combined use in patients may modify the contribution of each administered compound. Objective: To evaluate how treatment with calcifediol and/or corticosteroids in medical practice modified the need for ICU admission, death, or poor prognosis of patients hospitalized with COVID-19 during the first outbreaks. Design, patients and setting: A retrospective observational cohort study of patients admitted for COVID-19 to the Pneumology Unit of the Hospital Universitario Reina Sofía (Córdoba, Spain). Interventions: Patients were treated with calcifediol or/and corticosteroids with the best available therapy and standard care, according to clinical practice guidelines. Measurements: Admission to the intensive care unit (ICU) or death during hospitalization and poor prognosis. Results: Seven hundred and twenty-eight patients were included. According to the treatment received, they were included in four groups: calcifediol (n = 68), glucocorticoids (n = 112), both (n = 510), or neither (n = 38). Of the 578 patients treated with calcifediol, 88 were admitted to the ICU (15%), while of the 150 not treated with calcifediol, 39 required ICU admission (26%) (p < 0.01). Among the patients taking calcifediol without glucocorticoids, only 4 of 68 (5.8%) required ICU admission, compared to 84 of 510 (16.5%) treated with both (p = 0.022). Of the 595 patients who had a good prognosis, 568 (82.01%) had received treatment with calcifediol versus the 133 patients with a poor prognosis, of whom 90 (67.66%) had received calcifediol (p < 0.001). This difference was not found for corticosteroids. Interpretation: The treatment of choice for hospitalized patients with moderate or mild COVID-19 could be calcifediol, not administering corticosteroids, until the natural history of the disease reaches a stage of hyperinflammation. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.source | Entrenas-Castillo, M.; Entrenas-Costa, L.M.; Pata, M.P.; Jurado-Gamez, B.; Muñoz-Corroto, C.; Gomez-Rebollo, C.; Mira-Padilla, E.; Bouillon, R.; Quesada-Gómez, J.M. Calcifediol or Corticosteroids in the Treatment of COVID-19: An Observational Study. Nutrients 2024, 16, 1910. | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | Corticoids | es_ES |
dc.subject | Calcifediol | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | COVID-19 drug treatment | es_ES |
dc.subject | Vitamin D | es_ES |
dc.title | Calcifediol or Corticosteroids in the Treatment of COVID-19: An Observational Study | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/nu16121910 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |